Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

Biomedical Advanced Research and Development Authority

BARDA feature


Disaster Medicine

Sepsis training module developed through a BARDA and Sepsis Alliance partnership to address sepsis encountered in austere conditions following disasters

Medical responders have a new resource at their disposal to help in identifying and treating sepsis patients in austere environments: a 70-minute online training module entitled Disaster Medicine: Sepsis.  Learn More »


About BARDA

The Biomedical Advanced Research and Development Authority (BARDA) provides an integrated, systematic approach to the development of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies such as chemical, biological, radiological, and nuclear (CBRN) accidents, incidents and attacks; pandemic influenza (PI), and emerging infectious diseases (EID).

Together with its industry partners, BARDA promotes the advanced development of medical countermeasures to protect Americans and respond to 21st century health security threats.


Program Areas

CBRN
AMR
PI
EID

Portfolios

FDA Approvals
COVID-19 Portfolio
CBRN

Innovation and Partnerships

CARB-X
DRIVe
Blue Knight
BARDA Ventures
Culture of Innovation

Meet the Director, Gary Disbrow

Accomplishments

Ribbon icon
Syringe icon
Handshake icon
61
FDA approvals, licensures, and clearances

Enhancing the nation’s preparedness by partnering with innovators to make countermeasures available.
Learn More »
81
Biomedical products supported for COVID-19 response

Responding to the COVID-19 pandemic
by developing vaccines, therapeutics,
and diagnostics to help fight the virus.
Learn More »

142
BARDA-supported COVID-19 Partnerships

Partnering to develop products that are improving the ways Americans receive health care everyday.
Learn More »



BARDA TwitterBARDA LinkedInBARDA InstagramBARDA Subscribe

  • This page last reviewed: October 21, 2021